Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025748 · ClinicalTrials.gov registry record · NA
Ask Questions (ASQ):Implementation of a Communication Intervention
A NA study of Stage IV Breast Cancer and Stage II Breast Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
- 8
- Study locations
NCT05025748: Completed NA study of Stage IV Breast Cancer and Stage II Breast Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT05025748 is a NA study of Stage IV Breast Cancer and Stage II Breast Cancer that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 81 participants, above the 64-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (27% higher). The trial reports 8 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05025748, a NA study of Stage IV Breast Cancer and Stage II Breast Cancer, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
- 8
- Study locations
Study Summary
This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and patients' family want to ask the doctor.
Primary Outcome
20 items, 5-point Likert scale
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Intervention
Study Locations (8)
Michigan
- Karmanos Cancer Institute at McLaren Bay Region - Bay City
- Karmanos Cancer Institute at McLaren Clarkston - Clarkston
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute at McLaren Flint - Flint
- Karmanos Cancer Institute at McLaren Macomb - Mount Clemens
- Karmanos Cancer Institute at McLaren Central Michigan - Mount Pleasant
- Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey
- Karmanos Cancer Institute at McLaren Port Huron - Port Huron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2022-08-31 |
| Phase | NA |
What the finished NCT05025748 record still lists
NCT05025748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, above the 64-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (27% higher).
The record links to 10 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Behavioral Intervention is the first listed.
NCT05025748 lists 8 locations in 1 state (Michigan).
Frequently Asked Questions
What is clinical trial NCT05025748 about?
NCT05025748 is a clinical study titled "Ask Questions (ASQ):Implementation of a Communication Intervention". This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and pati...
What is the current status of trial NCT05025748?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2021-08-25. Estimated completion is 2022-08-31.
What conditions does trial NCT05025748 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage IV Lung Cancer, Stage II Prostate Cancer.
What interventions are being tested in trial NCT05025748?
The interventions under investigation include: Behavioral Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05025748?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05025748 being conducted?
This trial has 8 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05025748's enrollment target sits among peer trials
81 5th of 30 higher than 26 of 30 other Stage IV Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
RECRUITING · NA
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
COMPLETED · NA
-
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
COMPLETED · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI